PDMR-521955-158-R4 | Imaging characterization of a metastatic patient derived model of adenocarcinoma pancreas:

DOI: 10.7937/q37d-vh79 | Data Citation Required | Image Collection

Summary

Pre-clinical animal models of spontaneous metastatic cancer are infrequent; the few that exist are resource intensive because determination of the presence of metastatic disease, metastatic burden, and response to therapy normally require multiple timed cohorts with animal sacrifice and extensive pathological examination. We identified and characterized a patient derived xenograft model with metastatic potential, adenocarcinoma pancreas xenograft 521955-158-R4. In this study we performed a detailed imaging characterization (workflow below) of this model, which develops spontaneous lung metastases, details are provided in the attached standard operating procedures. Tumors in half of the mice were resected in the range 200-300 mm³ size; tumors in the other half were allowed to grow until it was necessary to euthanize them because of tumor size.

The imaging characteristics of this model (PDMR-521955-158-R4), which is available from the National Cancer Institute Patient-Derived Models Repository (https://pdmr.cancer.gov/), is highly favorable for preclinical research studies of metastatic disease when used in conjunction with non-contrast T2 weighted MRI.

Results: Adenocarcinoma pancreas (PDMR-521955-158-R4)

Table 1: Penetrance and location of pathological confirmed metastatic lesion(s).

Percent penetrance with respect to the average time-to-metastasis for non-resected (time from implant: 10.7 ± 1.8 weeks) and resected (time from tumor resection: 5.3 ± 1.1 weeks) cohorts.

PET/CT Characterization of the primary tumor:  Baseline PET (SOP attached) were performed when tumor reached an approximate 200 mm³.   Average SUVmax values (n=6) were calculated; [¹⁸F]FDG: 2.3 ± 0.8 and [¹⁸F]FLT: 2.4 ± 0.4.

Conclusion:

Good metastatic model with 40% penetrance un-resected and 70% with planned early resection.  Metastases are well observed on T2 MRI imaging allowing non-invasive evaluation in treatment trials.

Data Access

Version 1: Updated 2022/08/17

Additional Resources for this Dataset

The National Cancer Institute (NCI) has developed a national repository of Patient-Derived Models (PDMs) comprised of patient-derived xenografts (PDXs), in vitro patient-derived tumor cell cultures (PDCs) and cancer associated fibroblasts (CAFs) as well as patient-derived organoids (PDOrg). These models serve as a resource for public-private partnerships and for academic drug discovery efforts. These PDMs are clinically-annotated with molecular information and made available in the Patient-Derived Model Repository. Data related to the specific subjects in this Collection can be found at:

• PDMR-521955-158-R4

The NCI Cancer Research Data Commons (CRDC) provides access to additional data and a cloud-based data science infrastructure that connects data sets with analytics tools to allow users to share, integrate, analyze, and visualize cancer research data.

• Imaging Data Commons (IDC) (Imaging Data)

Citations & Data Usage Policy

Data Citation Required: Users must abide by the TCIA Data Usage Policy and Restrictions. Attribution must include the following citation, including the Digital Object Identifier: